As a professor, I write for a living. So it's only natural that I would turn to writing as I face a diagnosis of lung cancer. Instead of creating a CaringBridge site to keep people updated (I don't appreciate their donation pitches), I decided to start a blog. The first few entries are edited versions of what I posted on Facebook and sent via email in the first 2 weeks of this journey. June 9, 2022 Well, this is an unexpected turn of events. I am stuck at a hospital outside of Hamburg because they are testing me for TB. They can't do it until tomorrow and it takes a while to determine if I have it and if so, whether I'm infectious. Best case scenario is a couple days. If I have TB and am infectious, I will have to stay here 2 weeks. I started experiencing shortness of breath/fatigue while running last fall. Had a full work-up done of heart and lungs; everything came back normal except for iron. I figured the exercise fatigue was due to low iron plus menopause. Iron is ...
September 18 marked 38.6 months (3 years, 2 months, 18 days) since I first started taking Tagrisso. Why is 38.6 months significant? Because it is the median overall survival in the FLAURA study, a landmark study (2014-16) comparing Tagrisso and older targeted therapies among patients with advanced non-small cell lung cancer, EGFR mutation, and no prior treatment. 279 patients received Tagrisso and 277 people received an older drug (in addition, all patients received at least one dose of a trial drug). Nearly 58% of patients had died when data collection stopped. However, patients in the Tagrisso group lived nearly 7 months longer (median) than the control group. When Leland and I initially read that number – 38.6 months – in the Tagrisso promotional materials, we were stunned. This was supposed to be good news? The median age in the FLAURA study was 64 and at the time (August 2022), I had just turned 50. But still, it was a sobering statistic. For the longest time, I didn't feel ...